Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.46 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17698710 | 0.84 | BRD4 (0.47) | BRD4NSD3BRD2ERN1JAK2 | |
| SCHEMBL17698705 | 0.76 | NSD3 (0.50) | BRD4NSD3BRD2ACACBBRD3 | |
| SCHEMBL17581505 | 0.75 | BRD4 (0.68) | BRD4NSD3BRD2CREBBP | |
| SCHEMBL17698650 | 0.75 | BRD4 (0.41) | BRD4NSD3BRD2ACACBBRD3 | |
| SCHEMBL17698733 | 0.75 | BRD4 (0.52) | BRD4NSD3BRD2ACACBBRD3 | |
| SCHEMBL17698692 | 0.75 | ACACB (0.41) | BRD4NSD3BRD2ACACBCREBBP | |
| SCHEMBL17581483 | 0.74 | BRD4 (0.63) | BRD4NSD3BRD2JAK2CREBBP | |
| SCHEMBL17581434 | 0.71 | BRD4 (0.63) | BRD4NSD3BRD2JAK2BRD3 | |
| SCHEMBL17698700 | 0.71 | TRPA1 (0.46) | BRD4NSD3ACACB | |
| SCHEMBL17698651 | 0.71 | BRD4 (0.47) | BRD4NSD3BRD2ACACBBRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885NSD3 55/4885BRD2 3/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885NSD3 55/4885BRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.